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Objective: To determine the concentrations of granulocyte col0ny-stimulating factor (G-CSF) and interleukin (IL)-8 in 
sera from patients with Staphylococcus aureus septicemia and to correlate the results to peripheral neutrophil counts 
and the clinical outcome. 
Methods: Serum samples from 64 consecutive patients with S. aureus septicemia were sequentially collected in a 
prospective study. 
Results: The mean standard deviation (SD) serum G-CSF value on admission was 348 2 830 with a range of 8 to 5400 
pg/mL. G-CSF concentrations were elevated (> 76 pg/mL) in 38/64 patients (59%) as were serum IL-8 concentrations 
(> 67 pg/mL) in 23/64 patients (36%) on admission. The mean 2 SD IL-8 value was 266 2 422 pg/mL with a range of 2 to 
1366 pg/mL. A correlation was found between serum IL-8 and white blood cell count on admission ( p  = 0.008). 
Conclusions: Patients with uncomplicated septicemia frequently have elevated G-CSF values (84%) in comparison to 
patients with complicated septicemia (49%; p = 0.02), indicating a possible protective effect of G-CSF in septic 
complications. 
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Cytokines are important medators of the inflam- 
matory and immune responses in severe infections [l]. 
Much interest has been focused on gram-negative 
infections and the central role of endotoxid 
lipopolysaccharide (LPS) in initiating the 'sepsis 
cascade', thereby stimulating the release of various 
cytokines [2]. Staphylococcus aureus is a common and 
significant pathogen of serious infections such as 
septicemia. The pathogenesis of gram-positive infec- 
tions is not hlly understood and no such key factor as 
LPS/endotoxin in gram-negative infections has yet 
been demonstrated. In gram-positive infections, the 
importance of various cell-wall components and 
toxins as inducers of cytokine production has been 
investigated [3-71. 
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Granulocyte colony-stimulating factor (G-CSF) is 
a hematopoietic growth factor which stimulates the 
proliferation and differentiation of progenitor cells 
of neutrophil lineage [8,9]. This growth factor also 
enhances several functions of mature neutrophils and 
activates the process of phagocytosis [lo-121. G-CSF 
potentiates antibody-dependent as well as direct cellular 
cytotoxicity against infected cells [13,14]. Interleukin 
(1L)-8 is a cytokine with a potent chemoattractant 
effect [15,16]. IL-8 regulates neutrophil activation and 
migration [17,18] as well as degradation of neutro- 
phils [19], and also affects adhesion of neutrophils to 
endothelial cells [20]. 
Both G-CSF and IL-8 are produced by a number 
of cells, including monocytes/macrophages, fibroblasts 
and endothelial cells [21-261. The production can be 
stimulated by endotoxin/LPS from gram-negative 
bacteria and also by cytokines such as tumor necrosis 
factor (TNF)-a and IL-1 [17,21-23,261. Elevated 
serum G-CSF concentrations in serum samples from a 
limited number of patients with various infections have 
been reported [27-321, and IL-8 has also been detected 
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in sera from patients with clinical sepsis and septic 
shock [33-351 as well as in experimental endotoxinemia 
[36,37]. 
The aim of the present study was to determine the 
concentrations of G-CSF and IL-8 in sequential serum 
samples fiom patients with a well-defined gram- 
positive infection, such as septicemia caused by S. 
aureus, and to correlate the results to peripheral 
neutrophil counts and the clinical outcome. 
PATIENTS AND METHODS 
Patients admitted to the Department of Infectious 
Diseases at  the Orebro Medical Center Hospital during 
1988 to 1992 with S. aureus septicemia were included 
in this prospective study, which was approved by the 
Ethics Committee of the Orebro Medical Center 
Hospital. Sera fiom these patients were collected as 
soon as possible after S. aureus septicemia was suspected 
or verified. Samples were again collected at least 3 and 
7 days later, then once a week. Sera were stored at 
-7OOC pending analysis. The diagnosis of S. aureus 
septicemia was verified by positive blood cultures 
performed with Bactec@ 660 HP (Becton Dickinson, 
Towson, MD, USA). 
Patients 
G-CSF and IL-8 concentrations were assayed in 331 
serum samples h m  64 consecutive patients with 
verified S. aureus septicemia. The median age of the 
study population was 71 (range 10 to 91) years and 59% 
were men. Immunosuppression was found in seven 
patients and malignant diseases in four. Thirteen 
patients had diabetes mellitus and two had non- 
diabetic renal insufficiency. A total of 48 patients had 
community-acquired septicemia whereas 16 cases had 
been contracted during a hospital stay. None of the 
study patients had human immunodeficiency virus 
(HIV) infection. 
Two or more persistently positive blood cultures 
were found in 58 patients whereas only one positive 
blood culture was obtained fiom six patients. On 
admission, these patients displayed clinical signs of 
septicemia, including fever > 38.5”C, shaking chills, 
tachypnea, tachycardia, hypotension, leukocytosis 
and/or elevated C-reactive protein. 
Complicated septicemia, defined as a clinical 
course with septic metastasis such as acute osteo- 
myelitis, septic arthritis or extensive abscesses (long- 
standing, insufficiently drained), was found in 45 
patients; 15 patients fulfiied the criteria of endocarditis 
(one definite, six probable and eight possible) according 
to the strict case-definitions stated by von Reyn and 
colleagues [38]. Five patients (8%) died within a short 
time of the acute septicemic event (3 to 15 days after 
admission to hospital). Uncomplicated septicemia, 
defined as septicemia with no apparent metastatic foci, 
was seen in 19 patients. 
The study patients served as their own controls; 
they were followed-up throughout the clinical course 
of the disease and serum samples were collected 
sequentially. Serum samples fiom blood donors were 
analyzed as negative controls. 
Enzyme immunoassay 
The QuantikineTM human G-CSF immunoassay 
(R&D Systems, Minneapolis, MN) is a quantitative 
immunometric, ‘sandwich’-type, enzyme immuno- 
assay. Microtiter plates are coated with a specific 
monoclonal antibody against G-CSF acting as a capture 
antibody. Samples and standards (recombinant human 
G-CSF) are added and, after incubation and washings, 
horseradish peroxidase-labelled polyclonal antibodies 
against G-CSF are added. Following fkrther incubation 
and washings, substrate solution (tetramethylbenzidine) 
is added. Color development is stopped and optical 
density measured at 450 nm. 
The IL-8 enzyme-amplified sensitivity immuno- 
assay (EASIA; Medgenix Diagnostics, Fleurus, Belgium) 
is based on an oligoclonal system in which several 
monoclonal antibodies are directed against distinct 
epitopes of IL-8. The test gives a high sensitivity and a 
short incubation time. These assays were performed 
according to the manufacturer’s instructions. 
Blood donors 
In the blood-donor population, the upper limits for 
normal serum G-CSF and IL-8 concentrations were 
defined as mean values f 2 standard deviations (SD). In 
28 patients of this population, the mean G-CSF 
concentration was 36.6 f 19.7 (range 14 to 85) pg/mL 
with a cut-off point for normal G-CSF levels calculated 
as 76 pg/mL. In 20 patients in ths  population, the 
mean serum IL-8 concentration was 20.3 f 23.3 (range 
4 to 87) p g / d  and the normal cut-off point was 
67 pg/mL. 
Peripheral white blood cell (WBC) count 
This was determined accordmg to the routine method 
used in the Department of Clinical Chemistry. Normal 
WBC counts were defined as 4.0 to 9.0 x 109/L. 
Statistical analysis 
The Mann-Whitney U test was used for comparing 
the cytokine levels in different groups. Correlations 
between parameters were made using Spearman’s rank 
correlation test, and the chi-square test with continuity 
correction was used for comparing proportions. A p 
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value of < 0.05 was considered significant. The 
statistical software program StatView IITM was used for 
the calculations. 
RESULTS 
Kinetics of G-CSF in patients with S. aureus septicemia 
The serum G-CSF levels in 64 patients on admission 
with S. aureus septicemia are presented in Table 1 and 
Figure 1. On  adrmssion, 38/64 patients (59%) had 
elevated (> 76 p g / d )  G-CSF concentrations. In the 
remaining 26, G-CSF levels < 76 p g / d  were found, 
although four of these patients showed a rise in G-CSF 
(> 76 pg/mL) during the first day after admission, 
resulting in a total of 66% (42/64 patients) with 
elevated concenmtions of G-CSF on either admission 
or the following day. Six patients showed high serum 
G-CSF values (> 1000 pg/mL) on admission (Figure 1) 
but, in most cases, the initially high G-CSF values 
decreased rapidly within 1 week (Figure 2). 
There was a negative correlation (rs = -0.37, p = 
0.003) between delay (number of days from onset of 
the disease to admission) and G-CSF concentrations on 
admission. A significant difference (p = 0.007) in G- 
CSF values between patients with a short delay (< 1 
week) and those with a delay of 2 1 week (Figure 3) 
was also found. 
There was no correlation between G-CSF 
concentrations and WBC counts on adrmssion. Patients 
with an elevated (> 76 pg/mL) G-CSF concentration 
on admission did not have higher mean WBC counts 
than those with low or normal G-CSF concentrations 
(S 76 pg/mL). Six patients had high G-CSF values 
(> 1000 p g / d )  on admission, but their WBC counts 
were not higher than those with G-CSF values < 1000 
pg/mL. Only in one of these six patients with high 
admission G-CSF values did the WBC count increase 
during the course of the dlsease. 
On adrmssion, there w a s  a statistically significant 
difference in serum G-CSF concentration between 
patients with complicated septicemia and those with 
uncomplicated septicemia (p = 0.022; Table 1). The 
patients with complicated septicemia included both 
those with very high and low G-CSF values. Elevated 
serum G-CSF concentrations (> 76 pg/mL) were 
found in 16/19 patients (84%) with uncomplicated 
septicemia compared with 22/45 patients (49%) with 
complicated septicemia (p = 0.02; Figure 4). Five of the 
six patients with G-CSF concentrations > 1000 pg/mL 
had complicated septicemia. Patients with extensive 
abscesses (n = 15) had lower G-CSF levels than those 
without abscesses (Table l), but this difference was not 
significant. Patients with endocarditis (n = 15) had 
higher G-CSF values than those without signs of 
endocarditis (Table l), but the difference was not 
statistically significant (p = 0.07). There was no statis- 
tically significant difference in serum G-CSF levels 
between survivors and non-survivors (Tables 1 and 2). 
Table 1 Distribution of granulocyte colony-stimulating factor (G-CSF), interleukin-8 (IL-8) and white blood cell CSJBC) 
count at the time of hospital admission in 64 patients with Staphylococcus aureus septicemia 
Staphylococcus aurew septicemia (on adrmssion) 
Blood ALI Non- 
donors patients Compl , Uncompl EC Non-EC Abscess abscess Fatalities Survivors 
(n = 28) (n = 64) (n =45) (n = 19) (n = 15) (n = 49) (n = 15) (n = 49) (n = 5) (n = 59) 
G-CSF @g/mL) 
Mean 36.6 348 377 280 697 242 164 405 450 340 
(f SD) (f 19.7) (? 830) (? 959) (+ 396) (f 1417) (+ 518) (+ 294) (+ 930) (+ 841) (2 836) 
Median 32 93.5 55 125 180 80 54 110 50 95 
(...ge) (14-85) (8-5400) (8-5400) (50-1750) (26-5400) (8-3100) (26-1153) (8-5400) (10-1950) (8-5400) 
IL-8 @g/mL.) 
Mean 20.3 266 318 144 307 254 584 170 436 252 
(k SD) (k 23.3) (f 422) (t 459) (2 294) (t 441) (+- 420) (+- 500) (t 347) (t 562) (+- 412) 
Median 9 31 27 35 56 18 537 18 65 27 
(range) (4-87) (2-1366) (2-1366) (3-981) (5-1271) (2-1366) (8-1366) (2-1282) (5-1055) (2-1366) 
WBC (x109/~)  
Mean 13.6 13.1 14.8 15.8 12.9 17.3 12.4 17.3 13.3 
(t SD) (5 6.8) (+ 7.1) (f 6.2) (+ 7.7) (t 6.5) (+ 8.6) (+ 5.8) (+ 12.6) (+ 6.2) 
Median 12 11.5 13.8 15.4 11.3 16.3 11 15.4 12.0 
(rang) (3.4-38.2) (3.4-38.2) (5-26.2) (3.4-26.6) (4.8-38.2) (7.5-38.2) (4.4-26.2) (5.4-38.2) (3.4-26.6) 
Compl = complicated; Uncompl = uncomplicated; EC = endocarditis. 



















Admission 1 week 2weeks 
Figure 1 Serum G-CSF concentrations in 64 patients with 
Staphylococcus aureus septicemia on admission, and after 1 
and 2 weeks. 
Kinetics of 11-8 in patients with S. aureus septicemia 
The serum IL-8 levels in 64 patients on admission 
with 5'. aureus septicemia are presented in Table 1 and 
Figure 2. Serum IL-8 concentrations were elevated 
(> 67 pg/mL) in 23/64 (36%) patients. In addition, the 
IL-8 concentrations in sera from three patients mse to 
> 67 pg/mL during the first day after admission; thus, 
a total of 26/64 patients (41%) showed elevated levels 
of IL-8 either on admission or during the following day. 
High concentrations on adrmssion (> 750 pg/mL) were 
found in 12/64 patients (Figure 2), but a rapid decrease 
in serum IL-8 was noted in most patients during the 
course of the disease (Figure 3). 
No overall correlation between delay and serum 
IL-8 concentrations was found. However, patients with 
a shorter delay (< 1 week) between the onset of disease 
and admission to hospital showed lower serum I L 8  
levels than those with a longer delay (3 1 week; Figure 
3; p = 0.056). There was a significant correlation 
between the serum IL-8 concentrations on admission 
and WBC counts (rr = 0.34; p = 0.008), and patients 
with elevated (> 67 pg/mL) IL-8 concentrations 
had higher mean WrBC counts than those with low 
(S 67 pg/mL) IL-8 concentrations 0, = 0.048). 
There was no statistically significant hfference in 
serum IL-8 concentrations on admission between 
patients with complicated septicemia and those with 
uncomplicated septicemia (Table 1). However, the 15 
patients with extensive abscesses showed significantly 
higher serum IL-8 levels compared with those without 
abscesses (p = 0.001), although there was no statistically 
significant difference in serum IL-8 concentration on 
admission between patients with and without endo- 
carditis. Non-survivors (n = 5) had higher serum IL-8 
values than survivors, but the difference was not 
statistically significant (Table 2). However, two of the 
non-survivors had high IL-8 levels (>lo00 pg/mL) and 
Table 2 Characteristics of five patients with Staphylococnrs aureus septicemia and a fatal outcome 
Age Delay' 




























1950 EC, defmite 
47 (80) Renal abscess 
50 (108) Uncomplicated 
septicemia 
195 SA, coxitis 
< 10 SA, coxitis 
















IL-8 = interleukin-8; G-CSF = granulocyte colony-stimulating factor; EC = endocarditis; SA = septic arthritis; DIC = disseminated 
intrawcular coagulation. 
a = number of days between onset of illness and admission to hospital. 
( ) = maximum white blood cell (WBC) count during the course of disease. 
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three had low IL-8 levels ( S  67 pg/mL.) on admission. 
One patient who died during the early phase of 
septicemia had a clinical picture of septic shock and low 
levels (5 pg/mL) of IL-8. A further four patients, all of 
whom died during a later phase of the disease, also 
showed low levels of IL-8 in their final phase. 
White blood cell counts in patients with S. aureussepticemia 
The leukocyte counts in 17 (27%) patients on 
admission with S. aureux septicemia (Table 1) were 
normal. There was no statistically significant difference 
in leukocyte count on admission between patients 
with complicated and uncomplicated septicemia nor 
between those with or without endocarditis. Patients 
with a fatal outcome (n = 5 ,  Tables 1 and 2) had higher 
WBC counts on admission than did survivors, but the 
difference was not statistically significant. 
IL-8 (pglrnL) 
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Figure 2 Serum IL-8 concentrations in 64 patients with 
Staphylococcus aureus septicemia on admission, and after 1 
and 2 weeks. 
DISCUSSION 
In a previous study, we described the kinetics of IL-6, 
TNF-a and IL-1 p in serum samples fkom patients with 
well-defined gram-positive infections such as S. aureus 
septicemia [39]. In the present study, we present the 
corresponding results regarding serum G-CSF and IL- 
8 concentrations. 
On admission, the majority (59%) of patients 
showed elevated serum G-CSF concentrations and 
about one-third (36%) had elevated serum IL-8 levels. 
The WBC counts were increased in most patients 
(73%) on admission. Previously, elevated serum levels 
of G-CSF have only been reported from a small 
number of patients with various bacterial infections, 
including bacteremia/septicemia [27-321. The kinetics 
of G-CSF during septicemia have not hitherto been 
reported. 
The kinetics of serum G-CSF levels have been 
studied in an experimental model [40] wherein G-CSF 
levels increased approximately 24 h after initiation of 
infection, reaching a maximum after 3 days. In the 
present study, patients with elevated G-CSF concen- 
trations showed a rapid decrease in parallel with 
initiation of treatment and clinical improvement. This 
rapid decline may be an effect of treatment or reflect 
the natural course of G-CSF kinetics during the acute 
phase of an infection. The latter explanation may be 
"=64 n= 
l< 0 
4 " 4 9  n=33 "349 
3 4  5-7 8-14 
Days after admission 
Figure 3 Mean serum levels (95% confidence intervals) of 
G-CSF (0) and IL-8 (B) during the first 14 days in 64 
patients with Staphylococcus aureus septicemia ( n  = patients 
analyzed at indicated time). 
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supported by the fact that patients with a short delay 
(< 1 week) had significantly higher levels of G-CSF 
compared with those with a longer delay (3 1 week; 
Figure 4). A negative correlation was also found 
between the serum G-CSF concentration on adrmssion 
and delay. 
The present study results show no overall 
correlation between serum G-CSF concentration and 
WBC count on adrmssion, which is in accordance with 
the findings of Kawakami and coworkers [27], who 
found no association between serum G-CSF level and 
WBC count in either healthy controls or patients with 
various infections. However, those patients had higher 
serum G-CSF levels as well as higher WBC counts 
during the acute phase of infection compared with the 
recovery phase. Nevertheless, administration of G-CSF 
(> 1 pg/kg/day) to healthy subjects resulted in a 
sustained dose-dependent increase in circulating 
neutrophil counts within 3 to 5 days; after stopping G- 
CSF treatment, the neutrophil counts returned to 
baseline levels within 4 to 7 days [41]. 
The patients in the present study who had 











Figure 4 Mean serum levels (95% confidence intervals) of 
G-CSF (0) and IL-8 (w) according to delay (number of days 
between onset of disease and admission to hospital) in 64 
patients with Staphylococcus aureus septicemia. 
n=46 n=18 
c 1  week 2 1 week 
mean G-CSF values on adrmssion compared with 
patients with uncomplicated septicemia. However, 
patients with complicated septicemia had lower median 
values than those with uncomplicated septicemia, 
reflecting the fact that the group with complicated 
septicemia included both patients with very high and 
patients with low G-CSF values. The most remarkable 
finding was that a majority (16119) of the patients with 
uncomplicated septicemia had elevated (> 76 pg/mL) 
G-CSF concentrations on admission, in contrast to 
only about half of the patients (22/45) with compli- 
cated septicemia (Figure 5). This may be an indication 
that a high G-CSF concentration may have a protective 
effect on the development of septic complications such 
that patients who are able to produce an increase in G- 
CSF levels in response to bacterial infection may be less 
prone to develop complicated septicemia with septic 
metastases such as septic arthritis, osteomyelitis and 
formation of abscesses. 
This possibility is supported by the findings in 
animal experimental infections [42] wherein pretreat- 
ment with G-CSF appears to increase the magnitude 
of the neutrophil response and thereby facihtate 
the recruitment of neutrophils to the inflammatory 
focus/tissue and more effectively reduce the bacterial 
load, limit proliferation of the bacteria and prevent 











Figure 5 Number of patients with or without elevated G- 
CSF levels on admission in complicated and uncomplicated 
Staphylococcus aureus septicemia. 
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accord with our results as patients with abscesses had 
lower G-CSF concentrations on admission than those 
who did not develop abscesses. Other experimental 
studies have shown that G-CSF can protect animals 
from lethal infections caused by various pathogens 
and, in addition, improve survival when G-CSF and 
antibiotics were combined [43-481. 
Similar studies have not been performed in 
humans, although patients with infections such as 
endocarditis [49] and acquired immunodeficiency 
syndrome (AIDS) with concomitant neutropenia [50] 
have been treated with G-CSE However, in studies 
where G-CSF has been administered to patients with 
chemotherapy-induced [50] and other drug-induced 
neutropenia [51], a reduction in the duration of 
neutropenia and the number of infections has been 
reported. 
However, patients with complicated septicemia, 
such as a septic metastasis, may seek medical attention 
later than those without septic complications, as a septic 
metastasis is usually preceded by a bacteremia and a 
patient is not admitted until symptoms fiom a localized 
infection, or bacteremia with origin from a focal 
infection, is recognized. This also underlines the 
difficulties in determining the precise time of initiation 
of infection and, thus, in establishing the actual delay. 
In previous studies, IL-8 was detected in serum and 
cerebrospinal fluid from patients with sepsis, septic 
shock and meningitis [33-351. No differences in serum 
IL-8 levels were found between patients with gram- 
negative and those with gram-positive infections [34]. 
Endotoxin [36,37] as well as IL-1 [52] and TNF-a [37] 
have been shown to induce IL-8 production in vivo. 
The kinetics of IL-6 and IL-8 were similar [37,52,53] 
with concentrations that peaked later than that of 
TNF-a. It was therefore suggested that the endotoxin- 
induced release of IL-8 is mediated by TNF-ct [37]. 
The effects of bacterial components from gram- 
positive organisms as inducers of IL-8 production have 
been investigated in only one, recently published, study 
[54]. Lipoteichoic acid (LTA) purified from S. aureus 
induced expression of IL-8 messenger ribonucleic 
acid (mRNA) and production of IL-8 from human 
peripheral blood monocytes. Cell-associated IL-8 has 
also been demonstrated in endocardial specimens from 
patients with acute S. aureus endocarditis. 
In the present study, a correlation was found 
between serum IL-8 concentration and WBC count, 
which is in accordance with the results of experi- 
mental studies of animals without septic shock that 
were challenged with Escherichia coli, LPS or IL-la 
[52]. Patients with elevated (> 67 pg/mL) or high 
(> 750 pg/mL) serum IL-8 levels on admission had 
significantly higher WBC counts compared with 
corresponding patients who had low serum IL-8 levels 
(S  67 pg/mL) or serum IL-8 levels S 750 pg/mL, 
respectively. 
However, in a study of patients with meningo- 
coccal disease [35], a negative correlation was found 
between serum IL-8 and peripheral blood leukocyte 
count. There were also higher levels of IL-8 in patients 
with septic shock compared with those without shock 
[35]. All five patients with a fatal outcome had septic 
shock and four of the five showed extremely high 
serum IL-8 concentrations; the remaining patient had 
no detectable IL-8 in the serum. Similar findings have 
also been reported in patients with sepsis and septic 
shock caused not only by gram-negative, but also by 
gram-positive, bacteria [34]. These earlier results are 
supported by the findings in the present study 
wherein two of five non-survivors had high IL-8 levels 
(> 1000 pg/mL) and three had low (a 67 pg/mL) 
levels. 
A sustained release of degraded microbial cell-wall 
components and exotoxins is conceivable if a septic 
metastasis such as an abscess is present, which may result 
in long-lasting and continuous stimulation of synthesis 
of neutrophlic chemoattractants such as IL-8 and, 
consequently, accumulation of neutrophils within the 
abscess. This may explain why patients with extensive 
abscesses had significantly higher serum IL-8 levels than 
those without abscesses. 
In conclusion, cytokines are among a number of 
important factors involved in the host response to acute 
infection. Both G-CSF and IL-8 medate a number 
of functional effects of neutrophils, which play a 
particularly important role in the defense against 
bacterial infection. However, among patients with S. 
aureus septicemia in the present study, 59% had elevated 
serum G-CSF concentrations and 36% had elevated IL- 
8 values on admission, indicating that other mechan- 
isms for neutrophil activation may also be present. 
These findings raise the question of whether low 
concentrations of G-CSF may indicate an insufficient 
activation of neutrophils and, thus, an increased risk of 
developing more extensive infection and secondary 
septic complications. IL-8 is a chemoattractant factor 
for neutrophils and, although local IL-8 production is 
important, elevated serum levels may be detected and 
correlate with the extent, severity and duration of 
infection. 
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